127 related articles for article (PubMed ID: 7904525)
1. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer.
Dalbagni G; Presti JC; Reuter VE; Zhang ZF; Sarkis AS; Fair WR; Cordon-Cardo C
Diagn Mol Pathol; 1993 Mar; 2(1):4-13. PubMed ID: 7904525
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic alterations in superficial and locally advanced human bladder cancer.
Presti JC; Reuter VE; Galan T; Fair WR; Cordon-Cardo C
Cancer Res; 1991 Oct; 51(19):5405-9. PubMed ID: 1680549
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations and prognosis in bladder tumors.
Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
[TBL] [Abstract][Full Text] [Related]
4. Role of chromosome 9 in human bladder cancer.
Miyao N; Tsai YC; Lerner SP; Olumi AF; Spruck CH; Gonzalez-Zulueta M; Nichols PW; Skinner DG; Jones PA
Cancer Res; 1993 Sep; 53(17):4066-70. PubMed ID: 8358736
[TBL] [Abstract][Full Text] [Related]
5. [Genetic alterations in the region of the p53 gene on human chromosome 17 in colorectal cancer].
Kashkin KN; Fleĭshman EV; Chumakov PM; Perevoshchikov AG
Genetika; 1998 Aug; 34(8):1049-55. PubMed ID: 9777351
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53 and 17p allelic loss in colorectal carcinoma.
Cunningham J; Lust JA; Schaid DJ; Bren GD; Carpenter HA; Rizza E; Kovach JS; Thibodeau SN
Cancer Res; 1992 Apr; 52(7):1974-80. PubMed ID: 1551126
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
8. An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer.
Miyamoto H; Shuin T; Ikeda I; Hosaka M; Kubota Y
J Urol; 1996 Apr; 155(4):1444-7. PubMed ID: 8632608
[TBL] [Abstract][Full Text] [Related]
11. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas.
Wagata T; Shibagaki I; Imamura M; Shimada Y; Toguchida J; Yandell DW; Ikenaga M; Tobe T; Ishizaki K
Cancer Res; 1993 Feb; 53(4):846-50. PubMed ID: 8094033
[TBL] [Abstract][Full Text] [Related]
12. Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
Vet JA; Bringuier PP; Schaafsma HE; Witjes JA; Debruyne FM; Schalken JA
Lab Invest; 1995 Dec; 73(6):837-43. PubMed ID: 8558845
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
[TBL] [Abstract][Full Text] [Related]
14. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
[TBL] [Abstract][Full Text] [Related]
15. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses.
Denzinger S; Mohren K; Knuechel R; Wild PJ; Burger M; Wieland WF; Hartmann A; Stoehr R
Hum Pathol; 2006 Feb; 37(2):143-51. PubMed ID: 16426913
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.
Saxena A; Clark WC; Robertson JT; Ikejiri B; Oldfield EH; Ali IU
Cancer Res; 1992 Dec; 52(23):6716-21. PubMed ID: 1358438
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder.
Hartmann A; Schlake G; Zaak D; Hungerhuber E; Hofstetter A; Hofstaedter F; Knuechel R
Cancer Res; 2002 Feb; 62(3):809-18. PubMed ID: 11830537
[TBL] [Abstract][Full Text] [Related]
19. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
20. Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization.
Kobayashi M; Kawashima A; Mai M; Ooi A
Am J Pathol; 1996 Nov; 149(5):1575-84. PubMed ID: 8909247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
